Healthcare Jan 08, 2021 11:30 AM (GMT+8) · EqualOcean
Beijing Xinyi Bio Technology Co., Ltd. (hereinafter referred to as "Xinyi bio"), a digital PCR company, recently announced the completion of 150 million round B financing. This round of financing is led by Lilly Asia Fund, followed by Huachuang capital and hillhood venture capital. The financing funds will be used to promote the R & D and clinical trials of innovative molecular diagnostic reagents, promote the application of digital PCR products in life science and clinical fields, and accelerate their commercial layout. At present, Xinyi biological has established a product line covering tumor liquid biopsy, early tumor screening, early diagnosis of infectious diseases, rapid diagnosis of severe infection, birth defects and other important diseases.